Clinuvel Pharmaceuticals Ltd income statement

In fiscal 2026, Clinuvel Pharmaceuticals Ltd reported revenue of $64.3m, up 5.2% on the year before, operating income of $27.9m (a 43.4% margin) and net income of $23.2m, or $0.46 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Clinuvel Pharmaceuticals Ltd: income statement, annual
Fiscal year	2024Jun 2024	2025Jun 2025	2026Jun 2026
Revenue	58	61	64
Cost of revenue	11	12	11
Gross profit	47	50	53
Research and development	10	13	12
General and administrative	7	7	7
Operating income	29	27	28
Income before tax	33	33	33
Income tax	10	10	10
Net income	23	23	23
Diluted EPS	$0.46	$0.46	$0.46
Diluted shares (average)	51m	50m	51m
EBITDA	29	27	28

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABCL vs CUVL CUVL vs CYTK CUVL vs RXRX CUVL vs NTLA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Clinuvel Pharmaceuticals Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Clinuvel Pharmaceuticals Ltd.